Matches in SemOpenAlex for { <https://semopenalex.org/work/W2173632012> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2173632012 abstract "The anti-CTLA-4 antibody ipilimumab was the first immune checkpoint blockade antibody to show significant clinical efficacy. However, only a subset of the treated melanoma patients had long-term survival benefits (Schadendorf, D., et al. ECCO 2013). Combining ipilimumab with an agent that modulates immunity by a different mechanism may improve efficacy. Ibrutinib is a first-in-class, oral, covalent inhibitor of Bruton9s tyrosine kinase (Btk), an essential enzyme in the B-cell receptor signaling pathway. Ibrutinib also inhibits the interleukin-2-inducible Tec kinase (Itk) that is required for the activation/survival of Th2 T cells. This activity is consistent with preclinical studies that demonstrated ibrutinib could potentiate Th1 immunity (Dubovsky, JA., et al. Blood 2013). We investigated whether ibrutinib could enhance the anti-tumor effect of CTLA-4 blockade using the A20 B-cell lymphoma and the CT26 colon carcinoma mouse models. BALB/c mice (9-11/group) were implanted with tumor cells subcutaneously on the hind flanks. Animals bearing 80-100 mm3 (D x d2 x 0.4) tumors were dosed daily with oral ibrutinib (24 mg/kg) with or without the anti-mouse CTLA-4 antibody 9D9 (100 μg/mouse) given every 2 days by intraperitoneal injections. Animals in the lymphoma and colon cancer models were treated for 13 and 37 days, respectively. Tumor volume was measured and survival recorded for up to 2 months after tumor inoculation. Neither the A20 tumors, which express Btk, nor the CT26 tumors were inhibited by ibrutinib. In the A20 model, although 9D9 alone resulted in complete tumor regression in 7 of 9 treated animals, tumors in 2 of the 7 mice relapsed after treatment had ended. In contrast, 9D9 in combination with ibrutinib led to rapid, complete, and durable responses in 7 of 9 treated animals that lasted until the end of the study. In the CT26 model, treatment with 9D9 alone had minimal effects on tumor growth, but the addition of ibrutinib led to complete tumor regression in 6 of 10 treated animals. Thus, ibrutinib enhanced the anti-tumor efficacy of an anti-CTLA-4 antibody in B-cell lymphoma and colon carcinoma mouse models. The mechanism of tumor eradication by the combination therapy is under investigation and will be discussed at presentation. Citation Format: Patrick Ng, Daniel Lu, Betty Chang. Ibrutinib enhances the anti-tumor efficacy of CTLA-4 blockade in lymphoma and colon cancer models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 259. doi:10.1158/1538-7445.AM2015-259" @default.
- W2173632012 created "2016-06-24" @default.
- W2173632012 creator A5019139016 @default.
- W2173632012 creator A5020322482 @default.
- W2173632012 creator A5062625211 @default.
- W2173632012 date "2015-08-01" @default.
- W2173632012 modified "2023-09-26" @default.
- W2173632012 title "Abstract 259: Ibrutinib enhances the anti-tumor efficacy of CTLA-4 blockade in lymphoma and colon cancer models" @default.
- W2173632012 doi "https://doi.org/10.1158/1538-7445.am2015-259" @default.
- W2173632012 hasPublicationYear "2015" @default.
- W2173632012 type Work @default.
- W2173632012 sameAs 2173632012 @default.
- W2173632012 citedByCount "0" @default.
- W2173632012 crossrefType "proceedings-article" @default.
- W2173632012 hasAuthorship W2173632012A5019139016 @default.
- W2173632012 hasAuthorship W2173632012A5020322482 @default.
- W2173632012 hasAuthorship W2173632012A5062625211 @default.
- W2173632012 hasConcept C121608353 @default.
- W2173632012 hasConcept C126322002 @default.
- W2173632012 hasConcept C159654299 @default.
- W2173632012 hasConcept C170493617 @default.
- W2173632012 hasConcept C203014093 @default.
- W2173632012 hasConcept C2777701055 @default.
- W2173632012 hasConcept C2777938653 @default.
- W2173632012 hasConcept C2778461978 @default.
- W2173632012 hasConcept C2778468042 @default.
- W2173632012 hasConcept C2779338263 @default.
- W2173632012 hasConcept C2779878957 @default.
- W2173632012 hasConcept C2780851360 @default.
- W2173632012 hasConcept C2781433595 @default.
- W2173632012 hasConcept C42362537 @default.
- W2173632012 hasConcept C502942594 @default.
- W2173632012 hasConcept C526805850 @default.
- W2173632012 hasConcept C71924100 @default.
- W2173632012 hasConcept C8891405 @default.
- W2173632012 hasConcept C90059517 @default.
- W2173632012 hasConcept C98274493 @default.
- W2173632012 hasConceptScore W2173632012C121608353 @default.
- W2173632012 hasConceptScore W2173632012C126322002 @default.
- W2173632012 hasConceptScore W2173632012C159654299 @default.
- W2173632012 hasConceptScore W2173632012C170493617 @default.
- W2173632012 hasConceptScore W2173632012C203014093 @default.
- W2173632012 hasConceptScore W2173632012C2777701055 @default.
- W2173632012 hasConceptScore W2173632012C2777938653 @default.
- W2173632012 hasConceptScore W2173632012C2778461978 @default.
- W2173632012 hasConceptScore W2173632012C2778468042 @default.
- W2173632012 hasConceptScore W2173632012C2779338263 @default.
- W2173632012 hasConceptScore W2173632012C2779878957 @default.
- W2173632012 hasConceptScore W2173632012C2780851360 @default.
- W2173632012 hasConceptScore W2173632012C2781433595 @default.
- W2173632012 hasConceptScore W2173632012C42362537 @default.
- W2173632012 hasConceptScore W2173632012C502942594 @default.
- W2173632012 hasConceptScore W2173632012C526805850 @default.
- W2173632012 hasConceptScore W2173632012C71924100 @default.
- W2173632012 hasConceptScore W2173632012C8891405 @default.
- W2173632012 hasConceptScore W2173632012C90059517 @default.
- W2173632012 hasConceptScore W2173632012C98274493 @default.
- W2173632012 hasLocation W21736320121 @default.
- W2173632012 hasOpenAccess W2173632012 @default.
- W2173632012 hasPrimaryLocation W21736320121 @default.
- W2173632012 hasRelatedWork W1160892457 @default.
- W2173632012 hasRelatedWork W1967687206 @default.
- W2173632012 hasRelatedWork W1975865143 @default.
- W2173632012 hasRelatedWork W1978339413 @default.
- W2173632012 hasRelatedWork W2056011893 @default.
- W2173632012 hasRelatedWork W2070509149 @default.
- W2173632012 hasRelatedWork W2075970814 @default.
- W2173632012 hasRelatedWork W2078418747 @default.
- W2173632012 hasRelatedWork W2402590030 @default.
- W2173632012 hasRelatedWork W2479850754 @default.
- W2173632012 hasRelatedWork W2481519667 @default.
- W2173632012 hasRelatedWork W2495947690 @default.
- W2173632012 hasRelatedWork W2530488754 @default.
- W2173632012 hasRelatedWork W2546896473 @default.
- W2173632012 hasRelatedWork W2557679868 @default.
- W2173632012 hasRelatedWork W2584239571 @default.
- W2173632012 hasRelatedWork W2625832522 @default.
- W2173632012 hasRelatedWork W2979567920 @default.
- W2173632012 hasRelatedWork W3035108914 @default.
- W2173632012 hasRelatedWork W3180806010 @default.
- W2173632012 isParatext "false" @default.
- W2173632012 isRetracted "false" @default.
- W2173632012 magId "2173632012" @default.
- W2173632012 workType "article" @default.